<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570141</url>
  </required_header>
  <id_info>
    <org_study_id>9310-002-004</org_study_id>
    <nct_id>NCT00570141</nct_id>
  </id_info>
  <brief_title>OASIS Wound Matrix (Oasis) Mechanism of Action</brief_title>
  <official_title>Case Study Documentation of Subjects With Either Diabetic Foot Ulcers or Venous Stasis Ulcers Being Treated With OASIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OASIS Wound Matrix (Oasis) will be applied to wounds, with sequential biopsy of healing
      wounds to explore the mechanism of action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Wound types will be Diabetic Foot Ulcers (DFU) and Venous Stasis Ulcers (VSU).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in Wound Area From Baseline After 12 Weeks of Treatment or Until Wound Closure, Whichever Occurred First.</measure>
    <time_frame>Baseline and weekly up to 12 weeks</time_frame>
    <description>Wound measurements were made weekly, spaced 7 +/- 1 day apart, up to 12 weeks or until the wound healed, whichever occurred first.
The final measurement taken was subtracted from the baseline to assess the decrease in wound area after treatment.
Final calculation is mean baseline measurement minus final measurement at 12 weeks (or when wound healed, whichever occurred first)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Wounds Closed</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Wound healing was assessed weekly, spaced 7 +/- 1 day apart, up to 12 weeks or until the wound healed, whichever occurred first.
The outcome value was based on the percent of wounds which were closed at the end of the study (at 12 weeks). The percent wounds closed were calculated for each wound type: Diabetic Foot Ulcers (DFU) and Venous Stasis Ulcers (VSU).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Diabetic Foot Ulcers (DFU)</condition>
  <condition>Venous Stasis Ulcers (VSU)</condition>
  <arm_group>
    <arm_group_label>OASIS Wound Matrix (Oasis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is a single arm study with only the test article Oasis used on all subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OASIS Wound Matrix</intervention_name>
    <description>OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).</description>
    <arm_group_label>OASIS Wound Matrix (Oasis)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic foot ulcer (DFU) or venous stasis ulcer (VSU) of the leg, with certain
             restrictions on size, duration and underlying health

        Exclusion Criteria:

          -  Contraindications or hypersensitivity to the use of the study medications or their
             components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Payne, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bay Pines VA Healthcare System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Van Gils, DPM, CWS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dixie Regional Medical Center Wound Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davin Haraway, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sparks Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sparks Regional Medical Center</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixie Regional Medical Center Wound Clinic</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <results_first_submitted>June 9, 2010</results_first_submitted>
  <results_first_submitted_qc>July 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2010</results_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Innes Cargill, PhD, Director, Clinical Affairs Tissue Management</name_title>
    <organization>Healthpoint, Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OASIS Wound Matrix (Oasis)</title>
          <description>All subjects in this study were treated with OasisÂ®, there were no other test articles used in this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visits</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OASIS Wound Matrix (Oasis)</title>
          <description>All subjects in this study were treated with OasisÂ®, there were no other test articles used in this study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wound Type</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>DFU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VSU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in Wound Area From Baseline After 12 Weeks of Treatment or Until Wound Closure, Whichever Occurred First.</title>
        <description>Wound measurements were made weekly, spaced 7 +/- 1 day apart, up to 12 weeks or until the wound healed, whichever occurred first.
The final measurement taken was subtracted from the baseline to assess the decrease in wound area after treatment.
Final calculation is mean baseline measurement minus final measurement at 12 weeks (or when wound healed, whichever occurred first)</description>
        <time_frame>Baseline and weekly up to 12 weeks</time_frame>
        <population>Analysis was Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>OASIS Wound Matrix (Oasis)</title>
            <description>All subjects in this study were treated with OasisÂ®, there were no other test articles used in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Wound Area From Baseline After 12 Weeks of Treatment or Until Wound Closure, Whichever Occurred First.</title>
          <description>Wound measurements were made weekly, spaced 7 +/- 1 day apart, up to 12 weeks or until the wound healed, whichever occurred first.
The final measurement taken was subtracted from the baseline to assess the decrease in wound area after treatment.
Final calculation is mean baseline measurement minus final measurement at 12 weeks (or when wound healed, whichever occurred first)</description>
          <population>Analysis was Per Protocol</population>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diabetic Foot Ulcers (DFU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous Stasis Ulcers (VSU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Wounds Closed</title>
        <description>Wound healing was assessed weekly, spaced 7 +/- 1 day apart, up to 12 weeks or until the wound healed, whichever occurred first.
The outcome value was based on the percent of wounds which were closed at the end of the study (at 12 weeks). The percent wounds closed were calculated for each wound type: Diabetic Foot Ulcers (DFU) and Venous Stasis Ulcers (VSU).</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Analysis was Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>OASIS Wound Matrix (Oasis)</title>
            <description>All subjects in this study were treated with OasisÂ®, there were no other test articles used in this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Wounds Closed</title>
          <description>Wound healing was assessed weekly, spaced 7 +/- 1 day apart, up to 12 weeks or until the wound healed, whichever occurred first.
The outcome value was based on the percent of wounds which were closed at the end of the study (at 12 weeks). The percent wounds closed were calculated for each wound type: Diabetic Foot Ulcers (DFU) and Venous Stasis Ulcers (VSU).</description>
          <population>Analysis was Per Protocol</population>
          <units>Percent of Wounds Closed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diabetic Foot Ulcers (DFU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous Stasis Ulcers (VSU)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OASIS Wound Matrix (Oasis)</title>
          <description>All subjects in this study were treated with OasisÂ®, there were no other test articles used in this study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Follicular swelling</sub_title>
                <description>Infected insect bite - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection left foot 1st metatarsal head</sub_title>
                <description>Injury - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Osteomyelitis left foot 1st metatarsal head</sub_title>
                <description>Osteomyelitis - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Cellulitis left foot ulcer</sub_title>
                <description>Cellulitis of the foot, non-test ulcer - not related to the test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Open wound</sub_title>
                <description>Head wound - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <description>Biopsy pain - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Right leg pain - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister 2nd toe, left foot, with loose nail</sub_title>
                <description>Blister - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Achilles tendon repair</sub_title>
                <description>Tendon operation - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcer - right foot 5th toe medially</sub_title>
                <description>Skin ulcer - non-target ulcer - not related to test article</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Herbert B. Slade, M.D., FAAAI</name_or_title>
      <organization>Healthpoint, Ltd.</organization>
      <phone>917-900-4000</phone>
      <email>bert.slade@healthpoint.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

